Comments
Natco Pharma today reported over two fold jump in consolidated net profit to Rs 54.44 crore for the quarter ended March 31, 2015 mainly on account of a deferred tax reversal.
It had posted a net profit of Rs 24.02 crore in the year ago period, Natco Pharma said in a filing to BSE.
Total income from operations rose to Rs 200.80 crore for the quarter under review as against Rs 183.80 crore for same period year ago.
The company had a reversal of deferred tax liability of Rs 31.17 crore during the quarter.
During 2014—15 fiscal, the company posted a net profit of Rs 134.61 crore against Rs 102.74 crore in the previous year.
Total income also rose to Rs 825.27 crore as against Rs 738.89 crore.
In a separate filing to BSE, Natco Pharma said it’s board approved further issuance of shares or convertible securities in the form of private placement, Qualified Institutional Placement (QIP) to Foreign Institutional Investors (FIIs), Qualified Institutional Buyers or any other investors up to Rs 450 crore.
The board also approved increase of equity investment percentage in the company by Foreign Institutional Investors (FIIs)/Foreign Portfolio Investors etc to 49 per cent.
Merger of Natco Organics Ltd, a 100 per cent subsidiary firm into the company has also been approved by the Board, Natco Pharma said.
Shares of Natco Pharma today ended at Rs 2,295.40 on BSE, down 0.13 per cent from the previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.